Best Practice & Research Clinical Haematology最新文献_第9页

Targeted cellular therapy for treatment of relapsed or refractory leukemia 靶向细胞疗法治疗复发或难治性白血病

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-09-01 DOI: 10.1016/j.beha.2023.101481

Lauren D. Scherer , Rayne H. Rouce

{"title":"Targeted cellular therapy for treatment of relapsed or refractory leukemia","authors":"Lauren D. Scherer , Rayne H. Rouce","doi":"10.1016/j.beha.2023.101481","DOIUrl":"10.1016/j.beha.2023.101481","url":null,"abstract":"<div>While the mainstay of treatment for high-risk or relapsed, refractory leukemia has historically revolved around allogeneic hematopoietic stem cell transplant (allo-HSCT), targeted immunotherapies have emerged as a promising therapeutic option, especially given the poor prognosis of patients who relapse after allo-HSCT. Novel cellular immunotherapies that harness the cytotoxic abilities of the immune system in a targeted manner (often called “adoptive” cell therapy), have changed the way we treat r/r hematologic malignancies and continue to change the treatment landscape given the rapid evolution of these powerful, yet sophisticated precision therapies that often offer a less toxic alternative to conventional salvage therapies. Importantly, adoptive cell therapy can be allo-HSCT-enabling or a therapeutic option for patients in whom transplantation has failed or is contraindicated. A solid understanding of the core concepts of adoptive cell therapy is necessary for stem cell transplant physicians, nurses and ancillary staff given its proximity to the transplant field as well as its inherent complexities that require specific expertise in compliant manufacturing, clinical application, and risk mitigation. Here we will review use of targeted cellular therapy for the treatment of r/r leukemia, focusing on chimeric antigen receptor T-cells (CAR T-cells) given the remarkable sustained clinical responses leading to commercial approval for several hematologic indications including leukemia, with brief discussion of other promising investigational cellular immunotherapies and special considerations for sustainability and scalability.</div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"36 3","pages":"Article 101481"},"PeriodicalIF":2.1,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10458631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Describing and analyzing complex disease history in retrospective studies 在回顾性研究中描述和分析复杂的病史

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-09-01 DOI: 10.1016/j.beha.2023.101483

Ariane Boumendil , Myriam Labopin

引用次数: 0

Preface of special edition “Biostatistics in clinical haematology” 《临床血液学生物统计学》特刊前言

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-09-01 DOI: 10.1016/j.beha.2023.101486

Myriam Labopin, Ariane Boumendil

引用次数: 0

The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia 目前的情况:同种异体造血干细胞移植治疗急性淋巴细胞白血病

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-09-01 DOI: 10.1016/j.beha.2023.101485

Susan Prockop, Franziska Wachter

{"title":"The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia","authors":"Susan Prockop, Franziska Wachter","doi":"10.1016/j.beha.2023.101485","DOIUrl":"10.1016/j.beha.2023.101485","url":null,"abstract":"<div>One of the consistent features in development of hematopoietic stem cell transplant (HCT) for Acute Lymphoblastic Leukemia (ALL) is the rapidity with which discoveries in the laboratory are translated into innovations in clinical care. Just a few years after murine studies demonstrated that rescue from radiation induced marrow failure is mediated by cellular not humoral factors, E. Donnall Thomas reported on the transfer of bone marrow cells into irradiated leukemia patients. This was followed quickly by the first descriptions of Graft versus Leukemia (GvL) effect and Graft versus Host Disease (GvHD). Despite the pivotal nature of these findings, early human transplants were uniformly unsuccessful and identified the challenges that continue to thwart transplanters today – leukemic relapse, regimen related toxicity, and GvHD. While originally only an option for young, fit patients with a matched family donor, expansion of the donor pool to include unrelated donors, umbilical cord blood units, and more recently the growing use of haploidentical donors have all made transplant a more accessible therapy for patients with ALL. Novel agents for conditioning, prevention and treatment of GvHD have improved outcomes and investigators continue to develop novel treatment strategies that balance regimen related toxicity with disease control. Our evolving understanding of how to prevent and treat GvHD and how to prevent relapse are incorporated into novel clinical trials that are expected to further improve outcomes.Here we review current considerations and future directions for both adult and pediatric patients undergoing HCT for ALL, including indication for transplant, donor selection, cytoreductive regimens, and outcomes.</div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"36 3","pages":"Article 101485"},"PeriodicalIF":2.1,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10458625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transplantation and cellular therapy in acute leukemia 急性白血病的移植和细胞治疗

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-09-01 DOI: 10.1016/j.beha.2023.101499

Michael Grunwald, Belinda Avalos, Edward Copelan

引用次数: 0

The analysis of multiple outcomes, multiple variables and variables selection in hematopoietic cell transplantation studies 造血细胞移植研究的多结局、多变量及变量选择分析

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-09-01 DOI: 10.1016/j.beha.2023.101478

Soyoung Kim , Xi Fang , Kwang Woo Ahn

引用次数: 0

Hodgkin lymphoma: Focus on evolving treatment paradigms 霍奇金淋巴瘤:关注不断发展的治疗范式

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-08-17 DOI: 10.1016/j.beha.2023.101510

Joseph L. Roswarski , Dan L. Longo

引用次数: 0

Cytogenetics and genomics in pediatric acute lymphoblastic leukaemia 儿童急性淋巴细胞白血病的细胞遗传学和基因组学

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-08-17 DOI: 10.1016/j.beha.2023.101511

Željko Antić , Jana Lentes , Anke K. Bergmann

{"title":"Cytogenetics and genomics in pediatric acute lymphoblastic leukaemia","authors":"Željko Antić , Jana Lentes , Anke K. Bergmann","doi":"10.1016/j.beha.2023.101511","DOIUrl":"https://doi.org/10.1016/j.beha.2023.101511","url":null,"abstract":"<div>The last five decades have witnessed significant improvement in diagnostics, treatment and management of children with acute lymphoblastic leukaemia (ALL). These advancements have become possible through progress in our understanding of the genetic and biological background of ALL, resulting in the introduction of risk-adapted treatment and novel therapeutic targets, e.g., tyrosine kinase inhibitors for BCR::ABL1-positive ALL. Further advances in the taxonomy of ALL and the discovery of new genetic biomarkers and therapeutic targets, as well as the introduction of targeted and immunotherapies into the frontline treatment protocols, may improve management and outcome of children with ALL. In this review we describe the current developments in the (cyto)genetic diagnostics and management of children with ALL, and provide an overview of the most important advances in the genetic classification of ALL. Furthermore, we discuss perspectives resulting from the development of new techniques, including artificial intelligence (AI).</div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"36 4","pages":"Article 101511"},"PeriodicalIF":2.1,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49716024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytogenetics and molecular genetics of myelodysplastic neoplasms 骨髓增生异常肿瘤的细胞遗传学和分子遗传学

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-08-16 DOI: 10.1016/j.beha.2023.101512

Yi Ning , Yanming Zhang , Michael A. Kallen , Ashkan Emadi , Maria R. Baer

引用次数: 0

The presentation of results from studies in clinical haematology 临床血液学研究结果的介绍

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-06-01 DOI: 10.1016/j.beha.2023.101472

Richard M. Szydlo

引用次数: 0